BMY/BioNTech's Pumitamig Shows Encouraging NSCLC Efficacy; Phase 3 Underway

What happened

Bristol Myers Squibb and BioNTech reported encouraging global data from the Phase 2 ROSETTA Lung-02 study of Pumitamig, a first-in-class bispecific PD-L1xVEGF-A immunomodulator, in first-line non-small cell lung cancer (NSCLC) across PD-L1 levels and subtypes. In combination with chemotherapy, Pumitamig demonstrated robust anti-tumor activity at both doses, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose. The data support advancing Pumitamig into a registrational Phase 3 trial already actively recruiting, plus two additional global Phase 3 studies. While early, the response rates compare favorably to standard PD-1/PD-L1 inhibitor plus chemo regimens, but durability and safety still await full Phase 3 readout. This pipeline addition is positive for BMY's long-term growth portfolio but does not change the near-term focus on Eliquis margin stability and the 2026 bridge year.

Implication

The Pumitamig data incrementally strengthens BMY's pipeline credibility in immuno-oncology, potentially supporting a bull case if Phase 3 confirms durability and safety. However, the core investment thesis remains hinged on 2026 margin and Eliquis performance, not early-stage pipeline. Investors should treat this as a positive long-term catalyst but not a reason to exit the wait stance. The Phase 3 readout later this year or next will be a critical de-risking event.

Thesis delta

The core thesis remains unchanged: BMY is a wait until margin and Eliquis bridge confirm. Positive Pumitamig data modestly de-risks the pipeline and could lift bull case probability if Phase 3 succeeds, but does not alter the near-term margin focus. The news adds optionality for the pipeline but not enough to shift conviction away from the Eliquis-driven bridge year.